Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Lupin Limited ( (IN:LUPIN) ) has shared an announcement.
Lupin Manufacturing Solutions, a subsidiary of Lupin Limited, has announced a strategic alliance with PolyPeptide Group AG to enhance the global peptide supply chain. This collaboration aims to improve supply chain resilience, operational efficiency, and readiness for the growing peptides market, particularly in metabolic disease therapies. The partnership strengthens LMS’s position as a leading CDMO supplier and enhances PolyPeptide’s role as a trusted partner, ensuring reliable access to specialized materials for large-scale production and supporting the strategic growth of both companies.
More about Lupin Limited
Lupin Limited is a global pharmaceutical company with a subsidiary, Lupin Manufacturing Solutions (LMS), which specializes in the production of active pharmaceutical ingredients (APIs) and operates as a contract development and manufacturing organization (CDMO). LMS offers solutions across drug substances, complex chemistry, drug products, and advanced modalities, including antibody-drug conjugates (ADCs) and peptides, supporting biopharma innovators from early development to commercial scale.
Average Trading Volume: 25,576
Technical Sentiment Signal: Strong Buy
Current Market Cap: 937.3B INR
Learn more about LUPIN stock on TipRanks’ Stock Analysis page.